The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.
Abstract
This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated VH, and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL. This trial is registered at http://www.clinicaltrials.gov as no. NCT00267059.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immunomodulatory drugs, such as lenalidomide, have recently shown efficacy in CLL, although the mechanism of action remains obscure.35–37”
From RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans (2012) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S., & Dinarello, C. (1990) · Blood · doi:10.1182/blood.v75.1.40.40 · Cited by 1,012
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Research works printed but not linked: 23
- Keating, 2005, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia., J Clin Oncol, 23, 4009, 10.1200/JCO.2005.12.051 · DOI
- Keating, 2002, Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study., Blood, 99, 3554, 10.1182/blood.V99.10.3554 · DOI
- Keating, 2002, Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia., Leuk Lymphoma, 43, 1755, 10.1080/1042819021000006547 · DOI
- Tam, 2007, The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy., Leuk Lymphoma, 48, 1931, 10.1080/10428190701573257 · DOI
- Marriott, 2001, Immunotherapeutic and antitumour potential of thalidomide analogues., Expert Opin Bio Ther, 1, 675, 10.1517/14712598.1.4.675 · DOI
- Pellagatti, 2007, Lenalidomide inhibits the malignant clone and up-regulates the gene mapping to the commonly deleted region in 5q- syndrome., Proc Natl Acad Sci U S A, 104, 11406, 10.1073/pnas.0610477104 · DOI
- Mitsiades, 2007, Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment., J Cell Biochem, 101, 950, 10.1002/jcb.21213 · DOI
- Corral, 1999, Differential cytokine modulation and T-cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha., J Immunol, 163, 380, 10.4049/jimmunol.163.1.380 · DOI
- Ferrajoli, 2002, The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia., Blood, 100, 1215, 10.1182/blood.V100.4.1215.h81602001215_1215_1219 · DOI
- Cheson, 1996, National Cancer Institute-Sponsored Work Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment., Blood, 87, 4990, 10.1182/blood.V87.12.4990.bloodjournal87124990 · DOI
- Reuben, 2006, Biologic and immunomodulatory events after CTLA-4 blockade ticilimumab in patients with advanced malignant melanoma., Cancer, 106, 2437, 10.1002/cncr.21854 · DOI
- Schlette, 2005, Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19., Am J Clin Pathol, 123, 465, 10.1309/6Q27Q3NDGV8LW1BU · DOI
- Kini, 2000, Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia., Leukemia, 14, 1414, 10.1038/sj.leu.2401825 · DOI
- Thall, 1994, A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials., Control Clin Trials, 15, 463, 10.1016/0197-2456(94)90004-3 · DOI
- Thall, 1995, Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes., Stat Med, 14, 357, 10.1002/sim.4780140404 · DOI
- Chanan-Khan, 2006, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study., J Clin Oncol, 24, 5343, 10.1200/JCO.2005.05.0401 · DOI
- Kay, 2003, Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study [abstract]., Blood, 102, 359b
- Bartlett, 2004, Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers., Br J Cancer, 90, 955, 10.1038/sj.bjc.6601579 · DOI
- Tilg, 1994, Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55., Blood, 83, 113, 10.1182/blood.V83.1.113.113 · DOI · Paper page
- Zangari, 2005, Immunomodulatory drugs in multiple myeloma., Expert Opin Investig Drugs, 14, 1411, 10.1517/13543784.14.11.1411 · DOI
- Dredge, 2002, Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects., Br J Cancer, 87, 1166, 10.1038/sj.bjc.6600607 · DOI
- Neben, 2001, Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion., Br J Haematol, 115, 605, 10.1046/j.1365-2141.2001.03142.x · DOI
- Cibeira, 2008, Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents., Cytokine, 41, 244, 10.1016/j.cyto.2007.11.017 · DOI
Cited by
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Badoux, X. C., Keating, M. J., Wen, S., Wierda, W. G., O'Brien, S. M., Faderl, S., Sargent, R., Burger, J. A., & Ferrajoli, A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8623 · Cited by 158
Self-citationCrbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95
The application and biology of immunomodulatory drugs (IMiDs) in cancer
Pan, B., & Lentzsch, S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.004 · Cited by 76
Metadata
- Authors
- Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., Li, C., Reuben, J. M., & Keating, M. J.
- Affiliations
- Departments of Leukemia
- Hematopathology Research
- Hematopathology, and
- Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2008-06-01
- Volume
- 111
- Issue
- 11
- Pages
- 5291-5297
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 337
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2007-12-130120
- The paper
- Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., Li, C., Reuben, J. M., & Keating, M. J. (2008). Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood-2007-12-130120
